Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Shareholders agree to merger of the two wholesalers on Jan. 27. The combination of Cardinal Drug and Whitmire will create the third largest pharmaceutical wholesaler in the U.S. with estimated 1994 sales of $6 bil. The merger, announced Oct. 11 ("The Tan Sheet" Oct. 18, 1993, p. 3), is expected to be completed on or about Feb. 7. Whitmire stockholders will receive 3.85 mil. Cardinal shares. At current market prices, the Cardinal shares will be worth about $165.6 mil. Cardinal is also assuming Whitmire's debt of approximately $100 rail. Shareholders also approved proposals to rename the combined companies Cardinal Health and to expand the board of directors to 14 members

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts